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Background Cardiac amyloidosis (CA) is a secondary form of cardiomyopathy where abnormal accumulation of amyloid protein in the
myocardial interstitium causes cardiac hypertrophy and myocardial fibrosis. If primary CA advances to heart failure, most
patients do not survive for very long after the diagnosis.
...............................................................................................................................................................................................................
Case summary A 40-year-old man was admitted to our hospital for dyspnoea, progressive anaemia, and decreased appetite. He has diag-
nosed with amyloid light-chain (AL) amyloidosis. Although BD treatment (bortezomib þ dexamethasone) and medical
treatment were started, there was no sign of improvement. Then, high-dose chemotherapy followed by autologous per-
ipheral blood stem cell transplantation (auto-PBSCT) was initiated. Pretreatment echocardiography revealed typical find-
ings of CA, such as ventricular wall thickening, valvular thickening, diastolic dysfunction, and pericardial effusion. Global
longitudinal strain (GLS) was significantly reduced, and bull’s-eye mapping showed typical apical sparing. After auto-
PBSCT, GLS gradually improved and was almost normal after 2 years. Other echocardiographic parameters, functional sta-
tus, and laboratory data also showed that there was significant regression of CA.
...............................................................................................................................................................................................................
Discussion Although the prognosis in primary CA is extremely poor, we achieved long-term survival in a patient with effective high-
dose chemotherapy and auto-PBSCT. Global longitudinal strain may be a useful marker of prognosis, regression, and
recovery.
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Learning points
• Global longitudinal strain (GLS) may be a useful marker of regression and recovery after auto peripheral blood stem cell transplantation in
patients with cardiac amyloidosis (CA).
• Serial measurements of GLS may identify cardiac function improvement without demonstrable changes in standard echocardiographic
parameters among light-chain CA patients.
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Cardiac amyloidosis (CA) is part of a systemic disease characterized
by the deposition of amyloid in multiple tissues. Cardiac amyloidosis
results in characteristic macroscopic structural and functional
changes on transthoracic echocardiography (TTE).1 Global longitu-
dinal strain (GLS) is significantly reduced, and bull’s-eye mapping typ-
ically shows apical sparing.2 Cardiac amyloidosis is usually
accompanied by refractory heart failure and conduction abnormal-
ities; hence, most patients do not survive for very long after the diag-
nosis.3 However, recent reports have demonstrated that select
patients who achieve haematologic remission after high-dose chemo-
therapy and autologous peripheral blood stem cell transplantation
(auto-PBSCT) may regress these cardiac features.4,5 We report a pa-
tient with light-chain (AL)-CA who showed significant improvement
in the anatomic features associated with CA, including GLS.
Timeline
Case presentation
A 40-year-old man presented to a local clinic complaining of dys-
pnoea, progressive anaemia, and decreased appetite. N-terminal pro-
brain natriuretic peptide (NT-proBNP) was markedly elevated to
12 994 pg/mL, and he was admitted to our hospital. At the first visit,
his blood pressure was 84/46 mmHg and pulse rate was 65 b.p.m.
with a regular rhythm. Precordial examination revealed a third heart
sound. Chest examination revealed bilateral diminished air entry
over both lung bases. He displayed oedema of the lower extremities.
A blood test indicated markedly elevated levels of BNP (1490 pg/
mL). Complete blood count showed anaemia with haemoglobin of
10.9 g/dL.
Diagnostic assessment
Electrocardiography displayed a low-amplitude R-wave on the limb
leads and a QS pattern on leads V1–V3 (Figure 1A). Transthoracic
echocardiography revealed moderately increased left ventricular
(LV) wall thickness (septal wall, 14 mm; posterior wall, 14 mm) with a
small pericardial effusion (Figure 1B). Thickening of the right ventricu-
lar (RV) wall was also shown. Left ventricular systolic function was
preserved, with an ejection fraction (EF) of 63%, as measured by the
modified Simpson method. Longitudinal myocardial systolic strain
based on two-dimensional speckle-tracking echocardiography
showed far more significant LV dysfunction. Global longitudinal strain
was markedly reduced to -6.2%, and bull’s eye mapping revealed the
characteristic apical sparing pattern (Figure 1C). The regional values of
the RV free wall longitudinal strain (RV free wall LS) were reduced to
-7.0% (Figure 1D). Left atrial (LA) strain was also reduced to -14%.
The mitral inflow profile showed a restricted pattern such that the
patient’s peak early filling (E) and late diastolic filling (A) velocity ratio
was 3.2. Furthermore, the septal and lateral tissue Doppler e‘ values
were low, with an E/e’ ratio >15. Pulmonary artery systolic pressure
could not be estimated due to absence of tricuspid regurgitation.
Inferior vena cava (IVC) was dilated and showed decreased respira-
tory variability. These findings led us to strongly suspect CA with
heart failure. Cardiac magnetic resonance imaging (MRI) showed dif-
fuse subendocardial mild enhancement of the biventricular myocar-
dium. Subsequently, the patient was diagnosed with primary systemic
AL amyloidosis by cardiac muscle, duodenum, and bone marrow bi-
opsy (Supplementary material online, Figure S1).
Interventions and outcomes
Although BD treatment (bortezomib þ dexamethasone) and medic-
al treatment were started, the patient’s condition gradually wors-
ened. Then, high-dose chemotherapy (melphalan, 140 mg/m2) with
auto-PBSCT was started. The clinical course of auto-PBSCT is shown
in Figure 2. Brain natriuretic peptide levels declined to the 200 s pg/
mL at 6 months after auto-PBSCT and continued to decrease. Left
ventricular diastolic function measurements corresponded to pro-
gressive improvement in the BNP level. Doppler demonstrated a re-
laxation abnormality pattern with an E/A <0.8, and an IVC diameter
<15 mm at 6 months after auto-PBSCT. These improvements were
accompanied by an improvement in biventricular LS. While GLS
showed a slight change at 6 months after auto-PBSCT was started, it
significantly improved thereafter. Twenty-two months after auto-
PBSCT, GLS improved to a value of -16.2%, and bull’s-eye mapping
showed a more normal pattern. Right ventricular free wall LS and LA
strain were also improved to -17% and -27%, respectively. Left ven-
tricular EF did not change significantly from pretreatment levels. The
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Patient admitted to our hospital for dyspnoea,
progressive anaemia, and decreased appetite
Transthoracic echocardiography led us to
strongly suspect cardiac amyloidosis (CA)
with heart failure
1 month prior to
auto-PBSCT
Diagnosed with light-chain CA
BD treatment (bortezomib þ dexamethasone)
and medical treatment was started
February 2014 High-dose chemotherapy (melphalan,
140 mg/m2) with auto-PBSCT was started
Brain natriuretic peptide (BNP) = 1194 pg/mL,
global longitudinal strain (GLS) = -6.2%, and
left ventricular (LV) wall = 14 mm
4 months after
auto-PBSCT
Symptoms were getting relieved and discharged
hospital
BNP levels declined to the 700s pg/mL
6 months after
auto-PBSCT
BNP levels declined to the 200s pg/mL
GLS showed only a slight change (-8.3%)
11 months after
auto-PBSCT
BNP levels declined to the 80s pg/mL
GLS improved to a value of -12.2%




GLS improved to a value of -16.2%
LV wall improved to 10 mm
60 months after
auto-PBSCT
Patient has been no relapse and continues to
visit the outpatient clinic.
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anatomic changes in ventricular wall thickness occurred at a slower
rate than the changes in GLS. Left ventricular wall thickness improved
to 10 mm at 22 months after auto-PBSCT (Figure 3, Supplementary
material online, Videos S1 and S2). Interestingly, the subendocardial
enhancement disappeared on cardiac MRI after auto-PBSCT.
Currently, the patient has had no relapse over 60 months (Figure 4).
Discussion
Amyloid light-chain-CA is an infiltrative cardiomyopathy beginning
with subclinical myocardial deposition of fibrils, LV and RV wall thick-
ening, and impairment of diastolic function.6 Cardiac involvement
occurs in 50% of amyloidosis cases. As the volume of infiltration
increases, patients develop clinical heart failure with preserved EF.
Prognosis is poor, with survival reported as 48 months, dropping to
5–8 months with cardiac involvement.4
Our patient had a rapid reduction in BNP and has maintained a
good condition over a period of 5 years. This improvement may
have been due to shifting the treatment to high-dose melphalan and
Figure 1 Imaging examinations before treatment. (A) Electrocardiogram. (B) Parasternal echocardiographic view demonstrated biventricular
hypertrophy and a small pericardial effusion. (C) Bull’s-eye mapping. Regional values of the left ventricle longitudinal strain decreased markedly in the
base even though the apex remained unchanged, indicating an apical sparing pattern. (D) Regional values of the right ventricle free wall longitudinal
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Figure 2 Transthoracic echocardiography. Left ventricular car-
diac apex (upper), M mode view (middle), and speckle tracking
(lower). Although the left ventricular ejection fraction remained un-
changed at 60–65%, global longitudinal strain gradually improved.
Gradual alleviation of left ventricular wall hypertrophy was noted,
1 year after therapy.

























..auto-PBSCT. Plasma levels of the natriuretic peptides (BNP and NT-
proBNP) tend to be high in CA independent of the severity of heart
failure and have prognostic value as an index of response to therapy.7
In contrast, a recent study showed patients who achieve haemato-
logic remission after auto-PBSCT have significant regression of the
classical echocardiographic changes in CA.8 However, several studies
have reported that serial assessments of wall thickness and EF do in-
deed improve in association with a maintained complete haemato-
logic response, and these changes typically require many years (three
or more) to observe; they are rarely, if ever, observed in the short
term.9
Speckle-tracking echocardiography has been widely reported to
be useful in the diagnosis and prognosis of CA. Global longitudinal
strain and an apical sparing pattern have been widely reported to dis-
criminate between AL-CA and other wall thickening processes, and
predict survival associated with heart failure development in a cohort
of AL amyloidosis patients (cardiac and non-cardiac).2,10,11
Furthermore, several studies have reported that GLS may unmask
early cardiac recovery following chemotherapy in patients with CA.12
Fitzgerald et al.5 reported a case of an AL-CA patient who showed
complete remission with normalization of GLS 2 years after
PBSCT. In this previous case, the anatomic changes (regression in
wall thickness) occurred at a slower rate than the changes in GLS.
These findings are consistent with our case. Improvement in GLS
may be related to a reduction in the amount of myocardial amyloid
deposition. Ternacle et al.13 reported that areas with low strain
showed a tendency for higher levels of myocardial amyloid depos-
ition by histopathology of myocardial biopsies. A further analysis is
needed to determine whether or not our findings can be generalized
to other cases.
Conclusion
Our report provides detailed echocardiography follow-up of a pa-
tient throughout the clinical course of CA.
Lead author biography
Yukina Hirata is the sonographer at
Tokushima University Hospital. She
majored in cardiovascular Medicine
and received her PhD degree from
Graduate School of Medical
Sciences, Tokushima University,
Japan in March 2016. Her main re-
search theme is examine the clinical
utility of epicardial adipose tissue
using echocardiography. Recently,
she is interested in artificial intelli-
gence and supervised by Dr Kenya
Kusunose.
-16.0% -16.2%-12.2%-8.3%LV GLS:         -6.2%












Figure 3 Clinical course of the patient on high-dose chemotherapy with auto-PBSCT. After autologous peripheral blood stem cell transplantation,
the brain natriuretic peptide spiked to 1700 pg/mL, but declined to200 pg/mL after 6 months. These improvements were accompanied by a reduc-
tion in the global longitudinal strain levels.








































Supplementary material is available at European Heart Journal - Case
Reports online.
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